Paradigm Biopharmaceuticals has selected Advanced Clinical as the clinical research organisation (CRO) to support its pivotal ...

Paradigm Biopharmaceuticals continues to edge closer towards starting the pivotal phase III trial for its knee osteoarthritis ...

The GLP-1 receptor agonist exenatide failed to meet its primary outcome in a phase III trial of Parkinson's disease patients.

PhaseV has formed a strategic collaboration with Alimentiv for supporting the design and execution of adaptive clinical ...

Alphamab Oncology (Stock Code: 9966.HK) and CSPC Pharmaceutical Group Co., Ltd. ('CSPC') (Stock Code: 1093.HK) jointly announced that anti-HER2 biparatopic antibody-drug conjugate (ADC) JSKN003 has ...

Annovis Bio has commenced the treatment of subjects in a Phase III clinical trial of buntanetap in treating early Alzheimer's ...

Exenatide had no disease-modifying effects in a phase 3 trial Parkinson’s disease, despite earlier evidence from a phase 2 ...

After 2024, which saw a steady recovery by the life sciences industry, it looks like 2025 is set to be a year of change and ...

The waveLINE-010 trial will compare zilovertamab vedotin, in combination with rituximab plus cyclophosphamide, doxorubicin, and prednisone against the current standard-of-care in patients with ...

The company states the acquisition will further MERIT’s service offerings, allowing for a seamless transition from ...

GH Research shares were up 801 to $19.15 after the company said the primary endpoint was met in a Phase 2b clinical trial with GH001, an inhalable mebufotenin product candidate, in patients with ...

Treatment with exenatide, a GLP-1 receptor agonist, was comparable to placebo in slowing the rate of Parkinson’s disease ...